Revance Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Revance Therapeutics

08/08/2023 23:01

* Revance Therapeutics Inc  RVNC.OQ  reported a quarterly
adjusted
loss of 80 cents​​ per share for the quarter ended in June. The
mean expectation of twelve analysts for the quarter was for a
loss of 78 cents per share.
    * Revenue rose 104.9% to $58.13 million from a year ago;
analysts
expected $59.04 million. 
    * Revance Therapeutics Inc's reported EPS for the quarter
was a
loss of 80 cents​.
    * The mean earnings estimate of analysts had fallen by
about 8.7%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Revance Therapeutics Inc shares had fallen by 14.3% this
quarter and gained 17.6% so far this year.
    * The company reported a quarterly loss of $67.32 million.
    * Wall Street's median 12-month price target for Revance
Therapeutics Inc is $40.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 10:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.78          -0.80          Missed
 Mar. 31 2023      -0.70          -0.74          Missed
 Dec. 31 2022      -0.95          -0.95          Met
 Sep. 30 2022      -0.89          -1.17          Missed